StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report sent to investors on Friday. The firm issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
NASDAQ NBRV opened at $1.42 on Friday. Nabriva Therapeutics has a 12 month low of $1.22 and a 12 month high of $8.45. The company’s 50-day moving average is $0.14. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. The firm has a market cap of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53.
About Nabriva Therapeutics
Further Reading
- Five stocks we like better than Nabriva Therapeutics
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- MarketBeat Week in Review – 4/29 – 5/3
- How to Calculate Inflation Rate
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Insider Trades May Not Tell You What You Think
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.